Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis

Table 1

Clinical assessment of RA patients undergoing iguratimod treatment.

	Group A			Group B
	0 w	24 w	52 w	0 w	24 w	52 w
DAS28	6.11 ± 0.69	3.97 ± 1.31	3.85 ± 1.70	6.04 ± 0.72	5.65 ± 1.27	3.76 ± 1.69
ACR response rate, % of patients
ACR20		70.00	80.00		48.15	77.78
ACR50		56.67	56.67		18.52	50.00
ACR70		26.67	20.00		7.41	22.22

Clinical responses were defined according to the American College of Rheumatology 20% response criteria (ACR20), ACR50, and ACR70.